Predictable changes in the accuracy of human papillomavirus tests after vaccination: review with implications for … – Nature.com

International Agency for Research on Cancer. IARC Monographs on the evaluation of carcinogenic risks to humans: Biological agents (volume 100 B, 2012). URL: https://publications.iarc.fr/_publications/media/download/3007/d1d1e393a84cbb196956337642989bf03c8cd486.pdf. Last accessed: 29 December 2022.

Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens-Part B: biological agents. Lancet Oncol. 2009;10:3212.

Article PubMed Google Scholar

Muoz N, Bosch FX, Castellsagu X, Daz M, de Sanjose S, Hammouda D, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004;111:27885.

Article PubMed Google Scholar

Spayne J, Hesketh T. Estimate of global human papillomavirus vaccination coverage: analysis of country-level indicators. BMJ Open. 2021;11:e052016.

Article PubMed PubMed Central Google Scholar

Sonawane K, Lin Y-Y, Damgacioglu H, Zhu Y, Fernandez ME, Montealegre JR, et al. Trends in human papillomavirus vaccine safety concerns and adverse event reporting in the United States. JAMA Netw Open. 2021;4:e2124502.

Article PubMed PubMed Central Google Scholar

Hanley SJ, Yoshioka E, Ito Y, Kishi R. HPV vaccination crisis in Japan. Lancet. 2015;385:2571.

Article PubMed Google Scholar

Gountas I, et al. Impact of the COVID-19 pandemic on HPV vaccinations in Switzerland and Greece: road to recovery. Vaccines. 2023;11:258.

Article PubMed PubMed Central Google Scholar

UK Health Security Agency. Concern over drop in HPV vaccine coverage among secondary school pupils (Press release). URL: https://www.gov.uk/government/news/concern-over-drop-in-hpv-vaccine-coverage-among-secondary-school-pupils. Last accessed: 7 June 2023.

Simas C, Muoz N, Arregoces L, Larson HJ. HPV vaccine confidence and cases of mass psychogenic illness following immunization in Carmen de Bolivar, Colombia. Hum Vaccin Immunother 2019;15:1636.

Article PubMed Google Scholar

Palmer T, Wallace L, Pollock KG, Cuschieri K, Robertson C, Kavanagh K, et al. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study. BMJ. 2019;365:l1161.

Article PubMed PubMed Central Google Scholar

Thamsborg LH, Napolitano G, Larsen LG, Lynge E. High-grade cervical lesions after vaccination against human papillomavirus: a Danish cohort study. Acta Obstet. Gynecol. Scand. 2020;99:12906.

Article PubMed Google Scholar

Australian GovernmentAustralian Institute of Health and Welfare. Cancer Series Number 126: Analysis of cervical cancer and abnormality outcomes in an era of cervical screening and HPV vaccination in Australia (Cat. no. CAN 129). URL: https://www.aihw.gov.au/getmedia/479cc5bb-d698-4ff7-92fa-4be451b1897b/aihw-can-129.pdf.aspx?inline=true. Last accessed: 29 December 2022.

Drolet M, Benard E, Perez N, Brisson M. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019;394:497509.

Article PubMed PubMed Central Google Scholar

Rebolj M, Pesola F, Mathews C, Mesher D, Soldan K, Kitchener H. The impact of catch-up bivalent human papillomavirus vaccination on cervical screening outcomes: an observational study from the English HPV primary screening pilot. Br J Cancer. 2022;127:27887.

Article CAS PubMed PubMed Central Google Scholar

Lei J, Ploner A, Elfstrm KM, Wang J, Roth A, Fang F, et al. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med. 2020;383:13408.

Article CAS PubMed Google Scholar

Falcaro M, Castaon A, Ndlela B, Checchi M, Soldan K, Lopez-Bernal J, et al. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet. 2021;398:208492.

Article PubMed Google Scholar

Mix JM, Van Dyne EA, Saraiya M, Hallowell BD, Thomas CC. Assessing impact of HPV vaccination on cervical cancer incidence among women aged 15-29 years in the United States, 1999-2017: an ecologic study. Cancer Epidemiol Biomarkers Prev. 2021;30:3037.

Article PubMed Google Scholar

Palmer TJ, Kavanagh K, Cuschieri K, Cameron R, Graham C, Wilson A, et al. Invasive cervical cancer incidence following bivalent human papillomavirus vaccination: a population-based observational study of age at immunization, dose, and deprivation. J. Natl. Cancer Inst. 2024. https://pubmed.ncbi.nlm.nih.gov/38247547/. Online ahead of print

World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. URL: https://www.who.int/publications/i/item/9789240014107. Last accessed: 29 December (2022).

Landy R, Windridge P, Gillman MS, Sasieni PD. What cervical screening is appropriate for women who have been vaccinated against high risk HPV? A simulation study. Int J Cancer. 2018;142:70918.

Article CAS PubMed Google Scholar

Ronco G, Dillner J, Elfstrm KM, Tunesi S, Snijders PJF, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383:52432.

Article PubMed Google Scholar

Rebolj M, Cuschieri K, Mathews CS, Pesola F, Denton K, Kitchener H. Extension of cervical screening intervals with primary human papillomavirus testing: observational study of English screening pilot data. BMJ. 2022;377:e068776.

Article PubMed PubMed Central Google Scholar

Cuzick J, Clavel C, Petry K-U, Meijer CJLM, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119:1095101.

Article CAS PubMed Google Scholar

Maver PJ, Poljak M. Primary HPV-based cervical cancer screening in Europe: implementation status, challenges, and future plans. Clin Microbiol Infect. 2020;26:57983.

Article CAS PubMed Google Scholar

Pan American Health Organization. Integrating HPV testing in cervical cancer screening program: a manual for program managers. URL: https://iris.paho.org/bitstream/handle/10665.2/31393/9789275119105-eng.pdf?sequence=1&isAllowed=y. Last accessed: 29 December 2022.

Stubbs R. Significant landmark as primary HPV screening is offered across England. URL: https://phescreening.blog.gov.uk/2020/01/23/significant-landmark-as-primary-hpv-screening-is-offered-across-england/. Last accessed: 22 February 2021.

Snijders PJ, van den Brule AJ, Meijer CJ. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J Pathol. 2003;201:16.

Article PubMed Google Scholar

de Thurah L, Bonde J, Lam JUH, Rebolj M. Concordant testing results between various human papillomavirus assays in primary cervical cancer screening: systematic review. Clin Microbiol Infect. 2018;24:2936.

Article PubMed Google Scholar

Meijer CJLM, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer. 2009;124:51620.

Article CAS PubMed PubMed Central Google Scholar

Heideman DAM, Hesselink AT, Berkhof J, van Kemenade F, Melchers WJG, Fransen Daalmeijer N, et al. Clinical validation of the Cobas 4800 HPV test for cervical screening purposes. J Clin Microbiol. 2011;49:39835.

Article CAS PubMed PubMed Central Google Scholar

Heideman DAM, Hesselink AT, van Kemenade FJ, Iftner T, Berkhof J, Topal F, et al. The Aptima HPV assay fulfills the cross-sectional clinical and reproducibility criteria of international guidelines for human papillomavirus test requirements for cervical screening. J Clin Microbiol. 2013;51:36537.

Article CAS PubMed PubMed Central Google Scholar

Arbyn M, Simon M, Peeters E, Xu L, Meijer CJLM, Berkhof J, et al. 2020 list of human papillomavirus assays suitable for primary cervical cancer screening. Clin Microbiol Infect. 2021;27:108395.

Article CAS PubMed Google Scholar

Arbyn M, Depuydt C, Benoy I, Bogers J, Cuschieri K, Schmitt M, et al. VALGENT: A protocol for clinical validation of human papillomavirus assays. J Clin Virol. 2016;76:S14S21.

Article PubMed Google Scholar

Franceschi S, Clifford GM. Re: A study of the impact of adding HPV types to cervical cancer screening and triage tests. J Natl Cancer Inst. 2005;97:9389.

Article PubMed Google Scholar

Kitchener HC, Almonte M, Gilham C, Dowie R, Stoykova B, Sargent A. ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening. Health Technol Assess. 2009;13:1150.

Article CAS PubMed Google Scholar

Sand FL, Munk C, Frederiksen K, Junge J, Iftner T, Dehlendorff C, et al. Risk of CIN3 or worse with persistence of 13 individual oncogenic HPV types. Int J Cancer. 2019;144:197582.

Article CAS PubMed Google Scholar

Clifford G, Franceschi S, Diaz M, Munoz N, Villa LL. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine. 2006;24:S3/26S23/34.

Article PubMed Google Scholar

Rebolj M, Mathews CS, Pesola F, Cuschieri K, Denton K, Kitchener H. Age-specific outcomes from the first round of HPV screening in unvaccinated women: observational study from the English cervical screening pilot. BJOG. 2022;129:127888.

Article PubMed Google Scholar

Franco EL, Mahmud SM, Tota J, Ferenczy A, Coutlee F. The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change. Arch Med Res. 2009;40:47885.

Article PubMed Google Scholar

Kjaer SK, Nygrd M, Sundstrm K, Dillner J, Tryggvadottir L, Munk C, et al. Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries. EClinicalMedicine. 2020;23:100401.

Article PubMed PubMed Central Google Scholar

UK Health Security Agency. Correspondence: HPV vaccination programme: changes from September 2023 letter (Updated 29 June 2023). URL: https://www.gov.uk/government/publications/hpv-vaccination-programme-changes-from-september-2023-letter/hpv-vaccination-programme-changes-from-september-2023-letter. Last accessed: 2 December 2023.

Danish Medicines Agency. HPV vaccination. URL: https://laegemiddelstyrelsen.dk/en/sideeffects/side-effects-of-medicines/childhood-vaccines/hpv-vaccination/. Last accessed: 2 December 2023.

Dillner J, Rebolj M, Birembaut P, Petry K-U, Szarewski A, Munk C, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008;337:96972.

Article Google Scholar

Bonde J, Rebolj M, Ejegod DM, Preisler S, Lynge E, Rygaard C. HPV prevalence and genotype distribution in a population-based split-sample study of well-screened women using CLART HPV2 Human Papillomavirus genotype microarray system. BMC Infect Dis. 2014;14:413.

Article PubMed PubMed Central Google Scholar

Preisler S, Rebolj M, Untermann A, Ejegod DM, Lynge E, Rygaard C, et al. Prevalence of human papillomavirus in 5,072 consecutive cervical SurePath samples evaluated with the Roche cobas HPV real-time PCR assay. PLoS ONE. 2013;8:e59765.

Article CAS PubMed PubMed Central Google Scholar

HPV Information Centre. Statistics/Report Centre. URL: https://hpvcentre.net/datastatistics.php. Last accessed: 21 February (2023).

Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30:F123138.

Article CAS PubMed PubMed Central Google Scholar

Kavanagh K, Pollock KG, Cuschieri K, Palmer T, Cameron RL, Watt C, et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. Lancet Infect Dis. 2017;17:1293302.

Article PubMed Google Scholar

Bhatia R, Kavanagh K, Cubie HA, Serrano I, Wennington H, Hopkins M, et al. Use of HPV testing for cervical screening in vaccinated women-Insights from the SHEVa (Scottish HPV Prevalence in Vaccinated Women) study. Int J Cancer. 2016;138:292231.

Article CAS PubMed Google Scholar

van der Weele P, Breeuwsma M, Donken R, van Logchem E, van Marm-Wattimena N, de Melker H, et al. Effect of the bivalent HPV vaccine on viral load of vaccine and non-vaccine HPV types in incident clearing and persistent infections in young Dutch females. PLoS ONE. 2019;14:e0212927.

Article PubMed PubMed Central Google Scholar

Rebolj M, Njor S, Lynge E, Preisler S, Ejegod D, Rygaard C, et al. Referral population studies underestimate differences between human papillomavirus assays in primary cervical screening. Cytopathology. 2017;28:41928.

Article CAS PubMed Google Scholar

Thomsen LT, Frederiksen K, Munk C, Junge J, Iftner T, Kjaer SK. Long-term risk of cervical intraepithelial neoplasia grade 3 or worse according to high-risk human papillomavirus genotype and semi-quantitative viral load among 33,288 women with normal cervical cytology. Int J Cancer. 2015;137:193203.

Article CAS PubMed Google Scholar

Adcock R, Cuzick J, Hunt WC, McDonald RM, Wheeler CM. Role of HPV genotype, multiple infections, and viral load on the risk of high-grade cervical neoplasia. Cancer Epidemiol Biomarkers Prev. 2019;28:181624.

Article CAS PubMed PubMed Central Google Scholar

Castle PE, Xie X, Xue X, Poitras NE, Lorey TS, Kinney WK, et al. Impact of human papillomavirus vaccination on the clinical meaning of cervical screening results. Prev Med. 2019;118:4450.

Article PubMed Google Scholar

Kahn JA, Brown DR, Ding L, Widdice LE, Shew ML, Glynn S, et al. Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction. Pediatrics. 2012;130:e249e256.

Article PubMed PubMed Central Google Scholar

See the original post:

Predictable changes in the accuracy of human papillomavirus tests after vaccination: review with implications for ... - Nature.com